PMID- 10030375
OWN - NLM
STAT- MEDLINE
DCOM- 19990420
LR  - 20190718
IS  - 0021-9150 (Print)
IS  - 0021-9150 (Linking)
VI  - 142
IP  - 2
DP  - 1999 Feb
TI  - Heart allograft vascular disease: an obliterative vascular disease in 
      transplanted hearts.
PG  - 243-63
AB  - More than 30 years have passed since the first human heart transplantation was 
      performed. Since then, short-term survival after heart transplantation has been 
      markedly improved, but this development has not been paralleled with a similar 
      improvement in long-term survival. One of the major reasons for this is the 
      subsequent development of heart allograft vascular disease, an obliterative 
      disease in the coronary arteries of the transplanted heart. The dubious effect of 
      re-vascularization in this disease, the less favorable outcome after repeat heart 
      transplantation, and the low donor supply have called for intensified research 
      for new and efficient prophylactic therapies against heart allograft vascular 
      disease. This research has lead to improved knowledge about diagnosis, etiology, 
      pathogenesis, prophylaxis, and treatment possibilities. The most important among 
      these seem to be: (i) the introduction of intravascular ultrasound for early 
      detection of the disease; (ii) evidence to suggest that hyperlipidemia, 
      insufficient immunosuppressive therapy, human leukocyte antigen (HLA)-mismatch, 
      and infection with cytomegalovirus (CMV) all may promote allografts vascular 
      disease; and (iii) the introduction of at least two promising prophylactic 
      therapies in humans namely 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
      reductase inhibitors and calcium entry blockers, and others potentially promising 
      e.g. angiotensin-converting enzyme-inhibitors, angiopeptin, mycophenolate mofetil 
      and rapamycin. This review summarizes present knowledge on the possibilities of 
      inhibiting or treating heart allograft vascular disease incorporating evidence 
      from both human and experimental studies.
FAU - Orbaek Andersen, H
AU  - Orbaek Andersen H
AD  - Department of Cardio-Thoracic Surgery, R. Gentofte University Hospital, Hellerup, 
      Denmark.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Animals
MH  - *Arterial Occlusive Diseases/diagnosis/etiology/therapy
MH  - Follow-Up Studies
MH  - Graft Rejection/diagnosis/etiology/therapy
MH  - Heart Transplantation/*adverse effects
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Rats
MH  - Reoperation
MH  - Retrospective Studies
MH  - Risk Factors
RF  - 333
EDAT- 1999/02/25 00:00
MHDA- 1999/02/25 00:01
CRDT- 1999/02/25 00:00
PHST- 1999/02/25 00:00 [pubmed]
PHST- 1999/02/25 00:01 [medline]
PHST- 1999/02/25 00:00 [entrez]
AID - S0021-9150(98)00291-3 [pii]
AID - 10.1016/s0021-9150(98)00291-3 [doi]
PST - ppublish
SO  - Atherosclerosis. 1999 Feb;142(2):243-63. doi: 10.1016/s0021-9150(98)00291-3.